Regulatory

50 articles in this category (Page 3 of 3)

regulatoryproductearnings

ImmunityBio (IBRX) 21-Day Outlook: Increase Expected Amidst Global ANKTIVA Approvals Despite Overbought Technicals

ImmunityBio's massive 700% revenue growth and new international ANKTIVA approvals signal upside potential, though overbought technicals and deep negative margins cap confidence.

Feb 23, 2026IBRX

TechnologyRegulatoryMarket Analysis

Apple Inc. (AAPL) 21-Day Outlook: Sideways Consolidation Amid Mixed Regulatory and AI Signals

AAPL is poised for sideways movement as strong fundamental cash flows clash with FTC regulatory warnings and delayed AI rollouts.

Feb 21, 2026AAPL